NCT04400123 - A Bioequivalence Study of Famitinib Malate on Healthy Chinese Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 27, 2020

Primary Completion Date

July 18, 2020

Study Completion Date

July 18, 2020

Conditions

Healthy Adult Subjects

Interventions

DRUG

Famitinib malate

"TR group:~The first period，the subjects will be administrated with Famitinib malate in new formulation, then conduct blood collection within 192h; 14 days washout；The second period，the subjects will be administrated with Famitinib malate in old formulation, then conduct blood collection within 192h.~RT group:~The first period，the subjects will be administrated with Famitinib malate in old formulation, then conduct blood collection within 192h; 14 days washout；The second period，the subjects will be administrated with Famitinib malate in new formulation, then conduct blood collection within 192h."

Trial Locations (1)

100053

Xuanwu Hospital Beijing, Capital Medical University, Beijing

All Listed Sponsors

lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY